<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02558530</url>
  </required_header>
  <id_info>
    <org_study_id>Atkins</org_study_id>
    <nct_id>NCT02558530</nct_id>
  </id_info>
  <brief_title>Resolution of Liver Fat in Non-alcoholic Fatty Liver Disease</brief_title>
  <official_title>Rapid Resolution of Human Fatty Liver Disease, the Key to Obesity-related Morbidity and Mortality</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GÃ¶teborg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The major adverse health consequences of obesity occur only when non-alcoholic fatty liver&#xD;
      disease (NAFLD) also develops. NAFLD is characterized by abnormal hepatic accumulation of&#xD;
      triglycerides and other lipids. The first-line approach to NAFLD management is caloric&#xD;
      restriction and weight loss, but these remain difficult to achieve. Little attention has been&#xD;
      given to dietary carbohydrate restriction, despite recent reports showing that hepatic de&#xD;
      novo lipogenesis, a process that converts dietary carbohydrates into fatty acids in the&#xD;
      postprandial state, accounts for approximately 25% of liver triglyceride content in&#xD;
      hyperinsulinemic subjects with NAFLD. For comparison, only 15% of the liver triglycerides&#xD;
      were derived from dietary fatty acids in patients with NAFLD who had consumed a standardized&#xD;
      30% fat diet for four days before being assessed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To establish the time-course of hepatic fat loss in NAFLD subjects on a&#xD;
      carbohydrate-restricted diet (&lt;20 g/day), a serial assessments of liver fat during two week&#xD;
      diet will be performed. Also, markers of lipid and insulin metabolism, liver function test&#xD;
      and changes in gut microbiota during rapid metabolic improvement will be assessed.&#xD;
&#xD;
      The overall aim is to exploit this unique set of human material to determine the specific&#xD;
      cellular and molecular pathways that are modified in the early stages of metabolic&#xD;
      improvement and fatty liver regression.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">April 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Liver fat percent by nuclear magnetic resonance imaging</measure>
    <time_frame>14 days</time_frame>
    <description>Liver fat percent measured by nuclear magnetic resonance imaging</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>De novo lipogenesis measured as Incorporation of new fatty acids (%) to very-low density lipoprotein triglycerides</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut microbiota measured as change in microbiome profile from baseline</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>NAFLD</condition>
  <arm_group>
    <arm_group_label>Low carbohydrate diet</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Isocaloric diet, &lt;20 g carbohydrates per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Low carbohydrate diet</intervention_name>
    <description>Isocaloric, carbohydrate restricted diet 14 days</description>
    <arm_group_label>Low carbohydrate diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  increased liver fat above 5 % in magnetic resonance spectroscopy&#xD;
&#xD;
          -  body mass index 27-39.9 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  liver cirrhosis&#xD;
&#xD;
          -  portal hypertension&#xD;
&#xD;
          -  chronic liver disease other than NAFLD&#xD;
&#xD;
          -  diabetes mellitus or other significant endocrine disease&#xD;
&#xD;
          -  any medication acting on nuclear hormone receptors or inducing liver enzymes or&#xD;
             self-administration of supplements other than calcium or vitamins/trace elements&#xD;
&#xD;
          -  any significant cardiovascular co-morbidity&#xD;
&#xD;
          -  history of non-compliance&#xD;
&#xD;
          -  genotype (PNPLA3-MM and TM6SF2-TT) promoting liver fat accumulation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marja-Riitta Taskinen, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Helsinki</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>RPU Diabetes and Obesity, Biomedicum</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wllenberg Laboratory</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>September 21, 2015</study_first_submitted>
  <study_first_submitted_qc>September 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2015</study_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Marja-Riitta Taskinen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

